Market revenue in 2023 | USD 1,321.9 million |
Market revenue in 2030 | USD 1,951.7 million |
Growth rate | 5.7% (CAGR from 2023 to 2030) |
Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
Fastest growing segment | Antibody Drug Conjugate (ADC |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC |
Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.
Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 39.84% in 2023. Horizon Databook has segmented the Saudi Arabia active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.
Saudi Arabia accounted for 23.4% of the MEA’s market in 2020. Saudi Arabia’s FDA has created a stateof-the-art regulatory framework that supports clinical trials and development & manufacture of drugs & API in the country.
Furthermore, the availability of high-quality healthcare infrastructure, increase in number of industry experts trained in western medicine, rapidly growing investments in the contract industry, and increasing government initiatives are factors expected to boost the market in the country.
In March 2018, Saudi Pharmaceutical Industries & Medical Appliances Corporation signed an MoU with AstraZeneca for the launch of a contract manufacturing operation in the country. Growing number of clinical trials in the country is projected to create opportunities for the active pharmaceutical ingredient CDMOs.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account